Idexx Laboratories (IDXX) EBT (2009 - 2026)

Idexx Laboratories' EBT history runs 18 years deep, the most recent figure standing at $355.4 million for Q1 2026.

• In Q1 2026, EBT rose 14.63% year-over-year to $355.4 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 21.8% YoY), while the FY2025 annual figure was $1.3 billion, up 19.31% from the prior year.
• EBT was $355.4 million for Q1 2026 at Idexx Laboratories, up from $307.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $362.4 million in Q2 2025 to a low of $171.1 million in Q2 2022.
• Historically, EBT has averaged $277.1 million across 5 years, with a median of $267.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBT slumped 32.04% in 2022, then soared 67.13% in 2023.
• A 5-year view of EBT shows it stood at $213.2 million in 2022, then rose by 12.41% to $239.7 million in 2023, then advanced by 6.98% to $256.4 million in 2024, then increased by 19.73% to $307.0 million in 2025, then grew by 15.79% to $355.4 million in 2026.
• The last three EBT figures came in at $355.4 million (Q1 2026), $307.0 million (Q4 2025), and $344.8 million (Q3 2025), per Business Quant data.